Abstract:Abstract New nanomedicine formulations and novel applications of nanomedicinal drugs are reported on an almost daily basis. While academic progress and societal promise continue to shoot for the stars, industrial acceptance and clinical translation are being looked at increasingly critically. We here discuss five key challenges that need to be considered when aiming to promote the clinical translation of nanomedicines. We take the perspective of the end-stage users and consequently address the developmental path in a top-down manner. We start off by addressing central and more general issues related to practical and clinical feasibility, followed by more specific preclinical, clinical, and pharmaceutical aspects that nanomedicinal product development entails. We believe that being more aware of the end user’s perspective already early on in the nanomedicine development path will help to better oversee the efforts and investments needed, and to take optimally informed decisions with regard to market opportunities, target disease indication, clinical trial design, therapeutic endpoints, preclinical models, and formulation specifications. Critical reflections on and careful route planning in nanomedicine translation will help to promote the success of nanomedicinal drugs.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the main challenges encountered in the clinical translation process of nanomedicine. Starting from the perspective of end - users, the authors discuss five key challenges, aiming to promote the clinical translation of nanomedicines. These challenges specifically include: 1. **Commercial and Practical Feasibility**: Before considering the development of any nanomedicine, it is first necessary to evaluate the commercial and practical feasibility of its main target indications. This involves the potential degree of patient benefit and the size of the final patient population. 2. **Clinical Development Feasibility**: It is very difficult to prove better efficacy or safety, which requires large - scale and long - term clinical trials and a large amount of capital investment. Some key issues in clinical research design, such as selecting appropriate endpoint indicators to reflect the expected patient benefit and ensuring that these indicators are recognized by society (government agencies) and payers (insurance companies). 3. **Translating Pre - clinical Efficacy into Clinical Outcomes**: For nanomedicines, successfully translating pre - clinical efficacy into clinical outcomes may be more complex. This involves how to predict the variability in response rates and treatment effects among patients, especially in terms of the effects of tumor vascularization, interstitium, and macrophage populations on the targeted localization of nanoparticles and drug release. 4. **Linking Pre - clinical Toxicology with Patient Safety**: Nanomedicines may pose safety problems at three different levels. In addition to the inherent toxicity of the encapsulated active pharmaceutical ingredient itself, it also includes the change in the distribution of drug molecules in certain organs after being delivered by nanoparticles, which may lead to local over - exposure, and the unexpected toxicity that may be caused by excipients that have not been proven safe for humans. In addition, the immune response that is difficult to predict based on studies in small laboratory animals is also an important issue. 5. **Chemistry, Manufacturing and Control**: The management of chemistry, manufacturing and quality control (CMC) of nanomedicines is an important challenge. The in - vivo performance of nanomedicines, such as biodistribution, target accumulation, and drug availability at pathological and non - pathological sites, directly depends on the physicochemical properties of nanoparticles. Therefore, it is necessary to consider key quality attributes early in the formulation design and define a narrow specification range that can exhibit the best performance. By discussing these issues in detail, the authors hope to raise awareness of the end - user perspective, so as to have a clearer understanding of the overall efforts and investments required in the formulation design and laboratory experiment stages. This cautious route planning and navigation are crucial for helping experimental nanomedicine products finally fulfill the promise of increasing patient benefits.

Challenges in nanomedicine clinical translation

Editorial: Nanomedicine development and clinical translation

Progress, challenges, and future of nanomedicine

A translational framework to DELIVER nanomedicines to the clinic

Nanotechnology for modern medicine: next step towards clinical translation

Consideration for the scale‐up manufacture of nanotherapeutics—A critical step for technology transfer

The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.

Current approaches of nanomedicines in the market and various stage of clinical translation

Clinical Translation of Inorganic Nanoparticles and Engineered Living Materials for Cancer Therapy

Strategic aspects for the commercialization of nanomedicines

Towards principled design of cancer nanomedicine to accelerate clinical translation

Accelerating the Translation of Nanomaterials in Biomedicine.

Commentary: Nanoparticle-Based Chemotherapy Delivery and Potential Health Risks: Prospects for Effective Clinical Translation

Clinical Translation of Nanomedicine with Integrated Digital Medicine and Machine Learning Interventions

Obstacles and Recommendations for Clinical Translation of Nanoparticle System-Based Targeted Alpha-Particle Therapy

Nanomedicine Tumor Targeting

Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives

Diverse Applications of Nanomedicine

Current Developments and Applications of Microfluidic Technology Toward Clinical Translation of Nanomedicines.

Bridging the Gap between Clinical Practice and Translational Research

Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures